The need to update some particular aspects of bioequivalence testing and pharmacokinetic aspects of modified released formulations including transdermal patches has been recognised and a joint ad hoc group of experts of the Efficacy Working Party and Quality Working Party has been convened to deal with these issues under the chairmanship of Professor J.